XANTHINE-BASED CYCLIC GMP-ENHANCING RHO-KINASE INHIBITOR INHIBITS PHYSIOLOGICAL ACTIVITIES OF LUNG EPITHELIAL CELL LINE
    2.
    发明申请
    XANTHINE-BASED CYCLIC GMP-ENHANCING RHO-KINASE INHIBITOR INHIBITS PHYSIOLOGICAL ACTIVITIES OF LUNG EPITHELIAL CELL LINE 审中-公开
    基于XANTHINE的循环GMP-增强RHO-激酶抑制剂抑制肺上皮细胞系的生理活动

    公开(公告)号:US20100317671A1

    公开(公告)日:2010-12-16

    申请号:US12831544

    申请日:2010-07-07

    申请人: Ing-Jun Chen

    发明人: Ing-Jun Chen

    CPC分类号: A61K31/496 C07D473/08

    摘要: A pharmaceutical composition for a treatment of an interstitial lung disease is provided. The pharmaceutical composition comprises an effective amount of an active component being one selected from a group consisting of a KMUP compound, a KMUP monoquaternary ammonium salt and a KMUP monoquaternary ammonium complex salt, wherein the KMUP monoquaternary ammonium complex salt is synthesized by the KMUP compound and a carboxylic acid derivative of one selected from a group consisting of a statin, a non-steroid anti-inflammatory (NSAIDs) and an anti-asthmatic drug.

    摘要翻译: 提供了用于治疗间质性肺病的药物组合物。 药物组合物包含有效量的活性组分,其选自由KMUP化合物,KMUP单季铵盐和KMUP单季铵络合盐组成的组中的一种,其中KMUP单季铵络合盐由KMUP化合物合成, 选自他汀类,非类固醇抗炎药(NSAIDs)和抗哮喘药物的一种羧酸衍生物。

    Phenoxypropanol connected with phenylpiperazine and phenoxyalkylamine terminal in its side chain
    3.
    发明授权
    Phenoxypropanol connected with phenylpiperazine and phenoxyalkylamine terminal in its side chain 失效
    苯氧基丙醇与苯基哌嗪和苯氧基烷基胺末端在其侧链中连接

    公开(公告)号:US06846826B2

    公开(公告)日:2005-01-25

    申请号:US10105265

    申请日:2002-03-26

    申请人: Ing-Jun Chen

    发明人: Ing-Jun Chen

    CPC分类号: C07D213/80

    摘要: Certain 1,4-dihydropyridine compounds, useful as adrenergic blocking agents and as calcium channel blocking agents, the compounds having the formula wherein R1 is hydrogen, halogen, C1-6-alkyl, or C1-6-alkoxy, R3 is hydrogen, halogen, C1-6-alkyl, C1-6-alkoxy, or CF3(CH2)nO— wherein n is 1, 2, or 3, and R5 is —NHCH2CH2O— or —N(CH2CH2)2N—.

    摘要翻译: 某些可用作肾上腺素能阻断剂和钙通道阻断剂的1,4-二氢吡啶化合物,具有式R 1的化合物是氢,卤素,C 1-6 - 烷基或C 1-6 - 烷氧基,R 3 >为氢,卤素,C 1-6 - 烷基,C 1-6 - 烷氧基或CF 3(CH 2)n O-,其中n为1,2或3,R 5为-NHCH 2 CH 2 O-或-N(CH 2 CH 2) 2N-。

    Hypotensive intraocular pressure activity of clozapine and sulpiride
    4.
    发明授权
    Hypotensive intraocular pressure activity of clozapine and sulpiride 失效
    氯氮平和舒必利的低血压眼压活动

    公开(公告)号:US5744468A

    公开(公告)日:1998-04-28

    申请号:US736010

    申请日:1996-10-23

    CPC分类号: A61K31/40 A61K31/5513

    摘要: This invention introduces a novel anti-glaucoma solution which comprises of Clozapine or Sulpiride and a pharmaceutical vehicle. This is the first time all the above agents have been prepared in ophthalmologic solutions, which will be able to decrease the IOP in animals.

    摘要翻译: 本发明引入了一种新型的抗青光眼溶液,其中包括氯氮平或磺普利和药物载体。 这是所有上述药物首次在眼科溶液中制备,可以减少动物的眼压。

    Processes for preparing piperazinium salts of KMUP and use thereof
    6.
    发明授权
    Processes for preparing piperazinium salts of KMUP and use thereof 有权
    制备KMUP的哌嗪鎓盐的方法及其用途

    公开(公告)号:US08470805B2

    公开(公告)日:2013-06-25

    申请号:US12878451

    申请日:2010-09-09

    申请人: Ing-Jun Chen

    发明人: Ing-Jun Chen

    CPC分类号: A61K31/522 A61K2300/00

    摘要: A series of monoquarternary piperazium salts including a structure of a formula I or II are provided. In formula I or II, R1, Ra, and RX are as defined in the specification. The monoquarternary piperazium salt of KMUP or piperazine disclosed in the present invention is characterized by being presented in a pro-drug form and having various pharmaceutical functions.

    摘要翻译: 提供了包括式I或II结构的一系列单级哌嗪鎓盐。 在式I或II中,R1,Ra和RX如说明书中所定义。 本发明中公开的KMUP或哌嗪的单季哌嗪鎓盐的特征在于以前药形式存在并具有各种药学功能。

    KMUP-1 CAPABLE OF TREATING HYPERTENSION
    7.
    发明申请
    KMUP-1 CAPABLE OF TREATING HYPERTENSION 审中-公开
    KMUP-1可处理高血压

    公开(公告)号:US20110124655A1

    公开(公告)日:2011-05-26

    申请号:US13004586

    申请日:2011-01-11

    申请人: Ing-Jun CHEN

    发明人: Ing-Jun CHEN

    IPC分类号: A61K31/522 A61P9/00

    CPC分类号: A61K31/522

    摘要: A cardiomyocyte hypertrophy inhibiting pharmaceutical composition is provided. The composition comprises an effective amount of a compound of 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine; and a pharmaceutically acceptable carrier.

    摘要翻译: 提供抑制心肌细胞肥大的药物组合物。 该组合物包含有效量的7- [2- [4-(2-氯苯)哌嗪基]乙基] -1,3-二甲基黄嘌呤的化合物; 和药学上可接受的载体。

    Theophylline-based nitophenylpiperazine derivatives for enhancing aortic smooth muscle relaxation
    8.
    发明申请
    Theophylline-based nitophenylpiperazine derivatives for enhancing aortic smooth muscle relaxation 审中-公开
    基于茶碱的硝基苯基哌嗪衍生物,用于增强主动脉平滑肌松弛

    公开(公告)号:US20080064705A1

    公开(公告)日:2008-03-13

    申请号:US11520174

    申请日:2006-09-12

    申请人: Ing-Jun Chen

    发明人: Ing-Jun Chen

    IPC分类号: A61K31/522 C07D473/02

    CPC分类号: A61K31/522 C07D473/08

    摘要: A substance for enhancing an aortic smooth muscle relaxation is provided. The substance is one selected from the group consisting of a compound of formula (I), a pharmaceutical acceptable therefrom and a solvate therefrom, wherein either of R1 and R2 is one of a hydrogen and a nitro group.

    摘要翻译: 提供了用于增强主动脉平滑肌松弛的物质。 该物质是选自式(I)化合物,其可接受药物和其溶剂化物的化合物,其中R1和R2中的任一个是氢和硝基之一。

    Guaiacoxypropanolamines with alpha/beta adrenergic blocking activity
    10.
    发明授权
    Guaiacoxypropanolamines with alpha/beta adrenergic blocking activity 失效
    Guaiacoxypropanolamines具有α/β肾上腺素能阻滞活性

    公开(公告)号:US06518450B2

    公开(公告)日:2003-02-11

    申请号:US09740754

    申请日:2000-12-20

    申请人: Ing-Jun Chen

    发明人: Ing-Jun Chen

    IPC分类号: C07C22900

    摘要: The present invention reveals a novel structure of guaiacoxypropanolamines shown in formula I: The composition comprising formula I acts as active intergant and pharmaceutical acceptable vehicle. The composition by perfect administration routes in the mammal when given potential &agr;/&bgr;-adrenergic blocking, is selective for emergency hypertension.

    摘要翻译: 本发明揭示了式I所示的愈创木酚胺的新结构:包含式I的组合物作为活性中间体和药物可接受的载体。 当给予潜在的α/β-肾上腺素能阻断时,哺乳动物完美给药途径的组合物对于紧急高血压是有选择性的。